Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer
- 336 Downloads
Neoadjuvant endocrine therapy (NET) with Ki67-based response monitoring is a practical, cost-effective approach to the management of clinical stage II and III estrogen receptor-positive (ER+) breast cancer. In addition to marked improvements in rates of breast conservation, the identification of extreme responders on the basis of the preoperative endocrine prognostic index (PEPI) provides a rationale to avoid chemotherapy on the basis of highly favorable prognosis in some patients. Finally, samples accrued from patients treated with neoadjuvant therapy are providing valuable insights into the molecular basis for intrinsic resistance to endocrine therapy and promise a more rational basis and precise approach to the systemic treatment of ER+ breast cancer.
KeywordsBreast cancer Endocrine therapy Neoadjuvant Aromatase inhibitors Breast-conserving surgery
Compliance with Ethical Standards
Conflict of Interest
Tomás Reinert has received research funding from AstraZeneca and has received speaker’s honoraria from AstraZeneca, Novartis, and Pfizer.
Rodrigo Gonçalves declares that he has no conflict of interest.
Matthew J. Ellis has received clinical trial support from Novartis (P024 and Z1031 trials) and Pfizer (Z1031 trial); has received compensation from AstraZeneca, Pfizer, and Novartis for service as a consultant; and has licensed PAM50 patents to NanoString for Prosigna®. The commercial version of PAM50 is not mentioned within this article.
Human and Animal Rights and Informed Consent
Dr Ellis performed the Preoperative Letrozole Study and the Z1031 Study. He was a coinvestigator of the P024 Study. All these studies on human subjects were approved by the relevant ethics committees as outlined in the publications cited.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 10.Smith I. Preoperative endocrine therapy for operable breast cancer. In: Diseases of the breast 5th edition. 2014.Google Scholar
- 11.•• Ma C, Reinert T, Chmielewska I, Ellis M. Mechanisms of aromatase inhibitors resistance. Nat Rev Cancer. 2015;15:261–75. Comprehensive review of mechanisms of resistance to AIs cancer considering both genomic and cell biological explanatations as to why ER+ breast cancer cells progress and cause an incurable systemic disease.CrossRefPubMedGoogle Scholar
- 17.Mustacchi G, Ceccherini R, Milani S, Pluchinotta A, de Matteis A, Maiorino L, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol. 2003;14:414–20.CrossRefPubMedGoogle Scholar
- 23.Ellis M, Suman V, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol. 2011;29:2342–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Polley MYLS, Gao D, et al. An international study to increase concordance in Ki67 scoring. Mod Pathol. 2015;10Google Scholar
- 27.Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–16.CrossRefPubMedGoogle Scholar
- 29.Cataliotti L, Buzdar A, Noguchi S, Bines J, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast Cancer the pre-operative “arimidex” compared to tamoxifen (PROACT) trial. Cancer. 2006;106:2095–103.CrossRefPubMedGoogle Scholar
- 30.Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol. 2011;29:2342–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Semiglazov V. Neoadjuvant endocrine therapy: exemestane vs tamoxifen in postmenopausal ER+ breast cancer patients (T1–4, N1–2, M0). J Clin Oncol. 2005;23:Abstract 530.Google Scholar
- 33.Lerebours F, Bourgier C, Alran S, et al. Abstract PD07-04: a randomized phase II neoadjuvant trial evaluating anastrozole and fulvestrant efficiency for post-menopausal ER-positive, HER2-negative breast cancer patients: first results of the UNICANCER CARMINA 02 French trial. Cancer Res 2012;72(24 Suppl):Abstract nr PD07-04 2012.Google Scholar
- 34.Spring L, Gupta A, Reynolds K, et al. Neoadjuvant endocrine therapy for estrogen receptor–positive breast cancer a systematic review and meta-analysis. JAMA Oncol 2016; doi: 101001/jamaoncol20161897 Published online June 30, 2016.Google Scholar
- 35.•• Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100:1380–8. This paper established a prognostic model for ER+ breast cancer treated with neoadjuvant endocrine therapy based on the biological characteristics and pathological stage of the surgical specimen after completion of preoperative treatment.Google Scholar
- 38.Krainick-Strobel U, Lichtenegger W, Wallwiener D, et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer. 2008;8:62.CrossRefPubMedPubMedCentralGoogle Scholar
- 41.• Semiglazov V, Semiglazov V, Dashyan G, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110:244–54. This is one of the few randomized trials that prospectively compared endocrine therapy with chemotherapy in the neoadjuvant setting.CrossRefPubMedGoogle Scholar
- 42.ea COP. LBA9 – Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of luminal breast cancer. Results of the UNICANCER-NeoPAL study. Ann Oncol. 2017;Google Scholar
- 45.Guidance for Industry. Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2014. at https://www.fda.gov/downloads/drugs/guidances/ucm305501.pdf.)
- 47.Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32.CrossRefPubMedGoogle Scholar
- 49.Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol. 2011;29:2342–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.•• Ellis MJ, Suman VJ, Hoog J, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017;35:1061–9. This recently published paper evaluated the role of Ki67 as a surrogate marker for chemotherapy decision during and after NET.CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Olson JA Jr, Budd GT, Carey LA, et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009;208:906–14. discussion 15–6Google Scholar
- 53.• Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167–70. This publication introduced the role of Ki67 measurement as an early surrogate marker of the pattern of endocrine therapy resistance.CrossRefPubMedGoogle Scholar
- 55.Cohen AL, Factor RE, Mooney K, Salama ME, Wade M, Serpico V, et al. POWERPIINC (PreOperative window of endocrine therapy provides information to increase compliance) trial: changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen. Breast. 2017;31:219–23.CrossRefPubMedGoogle Scholar
- 59.• Goncalves R, Reinert T, Ellis MJ. Avoidance of negative results in adjuvant endocrine therapy trials for estrogen receptor-positive breast cancer. J Clin Oncol. 2017;35:2718–9. Short communication about the use of NET studies as a guide to the design of adjuvant endocrine therapy trials in early-stage breast cancer.CrossRefPubMedGoogle Scholar
- 68.Ma CX, Suman V, Goetz MP, et al. A phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer. Clin Cancer Res. 2017;Google Scholar
- 72.Hurvitz SA, Schilder JM, Frenzel M, Martín M. Abstract CT092: a phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH). Cancer Res. 2016;76:CT092-CT.CrossRefGoogle Scholar
- 73.•• Ma CX, Gao F, Luo J, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent Kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res. 2017;23:4055–65. Recently presented trial demonstrating benefit of adding the CDK4/6 inhibitor palbociclib to neoadjuvant AI. The improved efficacy in terms of higher rates of complete cell cycle arrest prompts additional evaluating of this class of drugs in both neoadjuvant and adjuvant trials of early-stage ER+ breast cancer.CrossRefPubMedPubMedCentralGoogle Scholar
- 79.Ma CX GF, Luo J, et al: NeoPalAna: neoadjuvant palbociclib, a cyclindependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer. Clin Cancer Res. 101158/1078-0432CCR-16-3206.Google Scholar